Comparative Pharmacology
Head-to-head clinical analysis: ARAZLO versus CORT DOME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAZLO versus CORT DOME.
ARAZLO vs CORT-DOME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation and immune responses, and inhibit phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Topical: Apply 0.045% gel once daily to affected areas of the face.
Hydrocortisone (Cort-Dome) typical adult dose: 100 mg intravenously or intramuscularly as a loading dose, followed by 50-100 mg intravenously every 6 hours for stress dosing; for replacement therapy: oral 20-30 mg daily in divided doses. Topical: apply sparingly to affected area 1-4 times daily.
None Documented
None Documented
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
Plasma half-life is approximately 1-2 hours; biological half-life (duration of adrenal suppression) is 18-36 hours.
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Primarily hepatic metabolism; renal excretion of inactive metabolites accounts for approximately 40-60% of elimination; less than 5% excreted unchanged in urine; biliary/fecal elimination is minor (<5%).
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid